What is Vir Biotechnology, Inc.'s SG&A?

Vir Biotechnology, Inc. (VIR) reported SG&A of $23.34M in Q1 2026.

How has Vir Biotechnology, Inc.'s SG&A changed year-over-year?

Vir Biotechnology, Inc.'s SG&A decreased by 2.5% year-over-year, from $23.94M to $23.34M.

What is the long-term trend for Vir Biotechnology, Inc.'s SG&A?

Over 4 years (2021 to 2025), Vir Biotechnology, Inc.'s SG&A has grown at a -13.0% compound annual growth rate (CAGR), from $160.79M to $92.07M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Vir Biotechnology, Inc. VIR SG&A

SG&A at other companies

AmgenAMGN

$1.6B-5.0%

Regeneron PharmaceuticalsREGN

$647.7M+2.3%

Gilead SciencesGILD

$1.45B+15.3%

Viridian Therapeutics, Inc.VRDN

$38.68M+126%

Nuvation BioNUVB

$38.31M+8.2%

ImmunityBio, Inc.IBRX

——

Segments

By segment

See full

Reportable Segment$23.34M-2.5%

Other financials

Income statement

See full

Revenue-$29.0K-101%

Gross profit$1.2M-60.2%

Operating income-$132.3M+5.2%

Net income-$125.7M-3.9%

EPS (diluted)-$0.85+3.4%

Balance sheet

See full

Cash & equivalents$283.0M-23.1%

Total debt$95.6M-0.5%

Total equity$812.8M-22.1%

Total assets$1.0B-21.6%

Cash flow

See full

Operating cash flow-$132.4M-69.5%

CapEx$390.0K-76.1%

Free cash flow-$132.8M-66.5%

Valuation

See full

Market cap$1.68B+61.1%

Profitability

See full

Gross margin96.1%-2.7pp

Operating margin-720.8%-313pp

Net margin-676%-291pp

FCF margin-686.5%-273pp

Returns & leverage

See full

Return on equity-47.7%+3.6pp

Debt / equity0.1×0.0×

Current ratio7.1×+0.3×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vir Biotechnology, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vir Biotechnology, Inc.'s SG&A?: Vir Biotechnology, Inc. (VIR) reported SG&A of $23.34M in Q1 2026.
How has Vir Biotechnology, Inc.'s SG&A changed year-over-year?: Vir Biotechnology, Inc.'s SG&A decreased by 2.5% year-over-year, from $23.94M to $23.34M.
What is the long-term trend for Vir Biotechnology, Inc.'s SG&A?: Over 4 years (2021 to 2025), Vir Biotechnology, Inc.'s SG&A has grown at a -13.0% compound annual growth rate (CAGR), from $160.79M to $92.07M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.